HMI-102

About Homology Medicines

Homology Medicines was a biotechnology company with a mission to develop curative genetic medicines for rare diseases through its dual-platform approach of gene therapy and nuclease-free gene editing. Its core assets were a suite of 15 human-derived AAVHSC vectors, which powered a clinical pipeline led by candidates for phenylketonuria (PKU). In March 2024, the company announced a strategic wind-down of its clinical programs, pivoting to seek partnerships or a sale of its intellectual property and technology platforms, marking a significant transition from drug developer to asset licensor.

Therapeutic Areas